Circulating estrogens and postmenopausal ovarian cancer risk in the women's health initiative observational study

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 4, 2016, Pages 648-656

  Trabert, Britton ^a   Brinton, Louise A ^a   Anderson, Garnet L ^b   Pfeiffer, Ruth M ^a   Falk, Roni T ^a   Strickler, Howard D ^c   Sliesoraitis, Sarunas ^d   Kuller, Lewis H ^e   Gass, Margery L ^f   Fuhrman, Barbara J ^g   Xu, Xia ^h   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b USA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; WOMEN'S HEALTH; AGED; BLOOD; CASE CONTROL STUDY; HEALTH; MIDDLE AGED; OVARIAN NEOPLASMS; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; GLOBAL HEALTH; HUMANS; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; OVARIAN NEOPLASMS; POSTMENOPAUSE; RISK FACTORS; WOMEN'S HEALTH;

EID: 84962393953     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1272-T     Document Type: Article

References (24)

1. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14:98-107.
2. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Men-opausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385:1835-42.
3. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, et al. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 2012;107:1181-7.
4. Wentzensen N, Trabert B, Schildkraut J. Ovarian cancer. In: Goldman MB, Troisi R, Rexrode KM, editors. Women and Health. Second ed. London, United Kingdom: Elsevier Inc.; 2013. p.1135-45.
5. Yang HP, Anderson WF, Rosenberg PS, Trabert B, Gierach GL, Wentzensen N, et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 2013;31:2146-51.
6. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000;7:73-83.
7. Erickson GF, Schreiber JR. Morphology and physiology of the ovary. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 921-35.
8. Lippert TH, Seeger H, Mueck AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 2000;65:357-69.
9. Nash JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989;73:1009-16.
10. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61:6768-76.
11. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 2000;36:657-66.
12. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013; 14:853-62.
13. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
14. Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 2003;104:636-42.
15. Dallal CM, Lacey JV Jr, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, et al. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B^FIT cohort. Horm Cancer 2016;7: 49-64.
16. Schock H, Surcel HM, Zeleniuch-Jacquotte A, Grankvist K, Lakso HA, Fortner RT, et al. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer 2014;21:831-44.
17. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010;171:45-53.
18. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 2012;131:938-48.
19. Fortner RT, Ose J, Merritt MA, Schock H, Tjonneland A, Hansen L, et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. Int J Cancer 2015;137:1196-208.
20. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
21. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13: S107-21.
22. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 2007;79:7813-21.
23. Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, et al. Circulating estrogens and estrogens within the breast among post-menopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat 2014; 143:517-29.
24. Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, et al. Relationship of serum estrogens and estrogen metabolites to postmeno-pausal breast cancer risk: a nested case-control study. Breast Cancer Res 2013;15:R34.